gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Rituximab binds CD20 on B cells; its Fc engages CD16A (FcγRIIIa) on NK cells to trigger ADCC (and complement activation), killing CD20+ targets, not the CD16A+ effector cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
IgG1 Fc engagement mediates ADCC via NK cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT04680962
disease_id_num_tar_ref
1672
drug_id_num_tar_ref
4519